12/21
10:19 am
bcrx
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 [Yahoo! Finance]
Low
Report
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 [Yahoo! Finance]
12/15
08:27 pm
bcrx
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? [Yahoo! Finance]
Low
Report
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? [Yahoo! Finance]
12/15
11:02 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
12/12
07:39 am
bcrx
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]
Medium
Report
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]
12/12
07:00 am
bcrx
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
Low
Report
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
12/4
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
04:28 pm
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/3
10:37 am
bcrx
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update [Yahoo! Finance]
Medium
Report
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update [Yahoo! Finance]
12/3
07:00 am
bcrx
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
Medium
Report
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
11/30
12:37 am
bcrx
BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers [Yahoo! Finance]
Low
Report
BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers [Yahoo! Finance]
11/27
02:45 pm
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
08:00 am
bcrx
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
Medium
Report
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
11/6
06:56 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/5
08:27 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Citizens Jmp from $27.00 to $25.00. They now have a "market outperform" rating on the stock.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Citizens Jmp from $27.00 to $25.00. They now have a "market outperform" rating on the stock.
11/5
07:01 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/5
07:00 am
bcrx
BioCryst to Present at Upcoming Investor Conference
Medium
Report
BioCryst to Present at Upcoming Investor Conference
11/4
09:06 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Barclays PLC from $11.00 to $9.00. They now have an "equal weight" rating on the stock.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Barclays PLC from $11.00 to $9.00. They now have an "equal weight" rating on the stock.
11/4
08:09 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
11/3
07:00 am
bcrx
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
10/24
04:32 pm
bcrx
Does BioCryst Stock Offer Value After a 7% Weekly Surge and Rare Disease Optimism? [Yahoo! Finance]
Low
Report
Does BioCryst Stock Offer Value After a 7% Weekly Surge and Rare Disease Optimism? [Yahoo! Finance]
10/23
07:00 am
bcrx
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
Low
Report
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
10/20
07:00 am
bcrx
BioCryst to Report Third Quarter 2025 Financial Results on November 3
Low
Report
BioCryst to Report Third Quarter 2025 Financial Results on November 3
10/15
10:33 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at Cantor Fitzgerald from $24.00 to $26.00. They now have an "overweight" rating on the stock.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at Cantor Fitzgerald from $24.00 to $26.00. They now have an "overweight" rating on the stock.
10/15
08:48 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) is now covered by analysts at TD Cowen. They set a "buy" rating and a $30.00 price target on the stock.
Medium
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) is now covered by analysts at TD Cowen. They set a "buy" rating and a $30.00 price target on the stock.
10/15
08:12 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at Needham & Company LLC from $17.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at Needham & Company LLC from $17.00 to $20.00. They now have a "buy" rating on the stock.